Second-generation BCR-ABL kinase inhibitors in CML.
Beyazit
Yavuz
Y
Kekilli
Murat
M
Haznedaroglu
Ibrahim C
IC
D001549:Benzamides; D000069439:Dasatinib; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000627:therapeutic use*; D012074:Remission Induction; D013844:Thiazoles / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D000069439:Dasatinib